Q-omics provides the consensus-scored UPK2 profile across patient tissues and cancer cell-line models. UPK2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, UPK2 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, UPK2 RNA expression shows 16,473 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where UPK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UPK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UPK2 survival associations across molecular data types. UPK2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UPK2 RNA expression–survival associations across cancer types. High UPK2 expression shows unfavorable associations in BRCA, ACC, SCLC, HNSC and PAAD, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for UPK2 RNA expression.
This table summarizes UPK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for UPK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UPK2 shows higher tumor expression in COAD, THCA, UCEC, KIRP, KIRC and LIHC. The COAD box plot shows higher UPK2 RNA expression in tumor versus normal tissue (log2 FC = +0.531, t-test p < 0.001).
This table shows molecular features associated with UPK2 in patient tissues and cancer cell lines. In patient samples, UPK2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, UPK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and URINARY_TRACT.
